Skip to main content

Advertisement

Table 4 Sensitivity and specificity of sAxl in CSF and plasma to discriminate between RIA and UIA

From: Identification of the soluble form of tyrosine kinase receptor Axl as a potential biomarker for intracranial aneurysm rupture

sAxl in CSF (n = 30/group)
Cut off (nM) Sensitivity % (95% CI) Specificity % (95% CI) LR+ LR-
0.02 100.00 (88.43 to 100.00) 13.33 (3.76 to 30.72) 1.15 0.00
0.09 90.00 (73.47 to 97.89) 66.67 (47.19 to 82.71) 2.70 0.15
0.10 86.67 (69.28 to 96.24) 70.00 (50.60 to 85.27) 2.89 0.19
0.11 76.67 (57.72 to 90.07) 83.33 (65.28 to 94.36) 4.60 0.28
0.12 73.33 (54.11 to 87.72) 90.00 (54.11 to 87.72) 7.33 0.30
0.14 63.33 (43.86 to 80.07) 93.33 (77.93 to 99.18) 9.50 0.39
sAxl in plasma (n = 20/group)
Cut off (nM) Sensitivity % (95% CI) Specificity % (95% CI) LR+ LR-
0.4 100 (83.16 to 100.0) 5 (0.1265 to 24.87) 1.05 0.00
0.5 90 (68.30 to 98.77) 15 (3.207 to 37.89) 1.06 0.67
1 80 (56.34 to 94.27) 45 (23.06 to 68.47) 1.45 0.44
1.2 65 (40.78 to 84.61) 65 (40.78 to 84.61) 1.86 0.54
1.7 50 (27.20 to 72.80) 80 (56.34 to 94.27) 2.50 0.63
  1. 95% CI, 95% confidence interval; LR+, positive likelihood ratio; LR-, negative likelihood ratio.